We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ZZ Biotech Initiates Phase 1 Study with 3K3A-APC
News

ZZ Biotech Initiates Phase 1 Study with 3K3A-APC

ZZ Biotech Initiates Phase 1 Study with 3K3A-APC
News

ZZ Biotech Initiates Phase 1 Study with 3K3A-APC

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ZZ Biotech Initiates Phase 1 Study with 3K3A-APC"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ZZ Biotech, LLC has announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for the treatment of acute ischemic stroke.

The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will investigate the safety and pharmacokinetics of single and multiple ascending doses of 3K3A-APC in healthy adult volunteers.

Approximately 62 eligible adult subjects will be assigned sequentially to 1 of 10 cohorts, at successively higher single doses, followed by successively higher multiple doses. Results of the study are anticipated in the first quarter of 2013.

The foundation for 3K3A-APC was laid by scientific work conducted in laboratories at the University of Southern California and The Scripps Research Institute.

Dr. Kent Pryor, Chief Operating Officer of ZZ Biotech, commented: "We are very pleased to have received approval from The Austrian Agency for Health and Food Safety (AGES) to initiate our first human study with 3K3A-APC. Our extensive preclinical studies into the neuroprotective effects of 3K3A-APC suggest that it is a promising candidate for the treatment of ischemic stroke."

Mr. Joseph Romano, Chief Executive Officer of ZZ Biotech, added: "Stroke is the No. 4 cause of death and the leading cause of adult disability in the United States. We are excited by the prospect of one day putting 3K3A-APC in doctors' hands to help reduce the tremendous suffering caused by stroke."

Advertisement